Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13

NeuroReport

Volumn 20, Issue 13, 2009, Pages 1193-1197

  Stanton, Patric K ^a   Potter, Pamela E ^b   Aguilar, Jennifer ^a   Decandia, Maria ^a   Moskal, Joseph R ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

Author keywords

Coagonist; Glycine site; Ischemia; NMDA receptor; Partial agonist; Stroke

Indexed keywords

GLYCINE; GLYX 13; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; GERBIL; HIPPOCAMPUS; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; TISSUE CULTURE;

ANIMALS; BRAIN ISCHEMIA; CAROTID ARTERY DISEASES; CELL DEATH; CELL HYPOXIA; FEMALE; GERBILLINAE; GLUCOSE; HIPPOCAMPUS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; STROKE; TIME FACTORS;

EID: 69549111246     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32832f5130     Document Type: Article

References (20)

1. Bothe HW, Bosma HJ, Hofer H, Hossmann KA, Angermeier WF. Selective vulnerability of hippocampus and disturbances of memory storage after mild unilateral ischemia of gerbil brain. Stroke 1986; 17:1160-1163. (Pubitemid 17008949)
2. Kotapka MJ, Gennarelli TA, Graham DI, Adams JH, Thibault LE, Ross DT, Ford I. Selective vulnerability of hippocampal neurons in acceleration-induced experimental head injury. J Neurotrauma 1991; 8:247-258.
3. Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res 2002; 136:467-486. (Pubitemid 35461000)
4. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 34:325-337. (Pubitemid 37021228)
5. McBain CJ, Kleckner NW, Wyrick S, Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol 1989; 36:556-565. (Pubitemid 19273831)
6. Wilcox KS, Fitzsimonds RM, Johnson B, Dichter MA. Glycine regulation of synaptic NMDA receptors in hippocampal neurons. J Neurophysiol 1996; 76:3415-3424. (Pubitemid 26378110)
7. Nilsson M, Carlsson A, Carlsson ML. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J Neural Transm 1997; 104:1195-1205. (Pubitemid 28031813)
8. Mothet JP, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc Natl Acad Sci (USA) 2005; 102:5606-5611. (Pubitemid 40530304)
9. Scharfman HE, Hodgkins PS, Lee SC, Schwarcz R. Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. Neurosci Lett 1999; 274:111-114. (Pubitemid 29457452)
10. Moskal JR, Yamamoto H, Colley PA. The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Curr Drug Targets 2001; 2:331-345. (Pubitemid 32821475)
11. Moskal JR, Kuo AG, Weiss C, Kelso S, O'Connor Hanson A, Wood PL, Disterhoft JF. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 2005; 49:1077-1087. (Pubitemid 41503306)
12. Zhang XL, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008; 55:1238-1250.
13. Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JD, Stanton PK, Moskal JR. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging May 13, 2009; [Epub ahead of print].
14. Ray AM, Owen DE, Evans ML, Davis JB, Benham CD. Caspase inhibitors are functionally neuroprotective against oxygen glucose deprivation induced CA1 death in rat organotypic hippocampal slices. Brain Res 2000; 867:62-69.
15. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6:53-60. (Pubitemid 43103819)
16. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 6:383-386.
17. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 2007; 27:2846-2857. (Pubitemid 46438991)
18. Nakanishi N, Tu S, Shin Y, Cui J, Kurokawa T, Zhang D, et al. Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci 2009; 29:5260-5265.
19. Nilsson A, Duan J, Mo-Boquist LL, Benedikz E, Sundström E. Characterisation of the human NMDA receptor subunit NR3A glycine binding site. Neuropharmacology 2007; 52:1151-1159. (Pubitemid 46335710)
20. Tong G, Takahashi H, Tu S, Shin Y, Talantova M, Zago W, et al. Modulation of NMDA receptor properties and synaptic transmission by the NR3A subunit in mouse hippocampal and cerebrocortical neurons. J Neurophysiol 2008; 99:122-132.